Hospital Ruber Internacional SA

Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness, communication and seizure severity 75% reduction in median seizure rate seen for patients in the long-term extension Registrational phase of the EMBOLD study for SCN2A and 8A initiated BOSTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today shared positive topline results for its Phase 2, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. “We are thrilled to see the combination of positive efficacy and tolerability of relutrigine for SCN2A and 8A, where there are no approved treatments. When comparing to the baseline rates, patients in EMBOLD had over 2,000 fewer seizures since the beginning of the study. This kind of remarkable impact keeps us focused on advancing our programs,” said Marcio Souza, president and chief executive officer. “Seizure freedom is the ultimate goal for patients, and we were humbled by the progress made with relutrigine during the EMBOLD study with over 30% of patients achieving this life-altering milestone. Most importantly, we are grateful to the patients, families, caregivers and clinicians who participated in the trial.” "With over 30 years of experience treating pediatric epilepsy, I am profoundly excited by the results we've seen in the EMBOLD Study. The meaningful reduction in seizures, with many patients experiencing a dramatic decrease, gives us real hope for improving the lives of these children” said Dr. Antonio Gil-Nagel, Director of the Epilepsy Program at the Ruber International Hospital and Principal Investigator for the EMBOLD Study. “Seeing over 30% of patients achieve seizure freedom and the remarkable improvements in their alertness and communication are especially encouraging. The magnitude of these results suggests that relutrigine could truly transform the landscape of pediatric epilepsy treatment”. “On behalf of the international SCN2A and SCN8A communities, whose loved ones face severe, life-threatening health challenges due to devastating seizures and the absence of approved treatments, we are optimistic about the initial results from EMBOLD. The achievement of significant reduction in seizures compared to placebo could represent a meaningful improvement in the lives of these children and their families. While early, the signals of seizure freedom and positive outcomes across multiple clinical assessments are also promising. We are very excited that the next phase of the study is already initiated, and we remain hopeful that this drug will prove to be a valuable therapy for our community, offering much-needed relief and hope,” said Kacie Craig, Gabi Conecker, Kris Pierce and Shawn Egan, in a joint statement from The Cute Syndrome Foundation, International SCN8A Alliance, SCN2A Australia, and the FamilieSCN2A Foundation. About the EMBOLD StudyEMBOLD is a multicenter, double-blind, placebo-controlled, intervention-period-masked, randomized study, followed by open-label extension (OLE), which enrolled eligible male and female participants aged 2-18 years with a diagnosis of early onset SCN2A-DEE or SCN8A-DEE. Sixteen patients were randomized (1:1) to receive relutrigine QD for 16 weeks, or relutrigine QD for 12 weeks and matching placebo QD for 4 weeks, administered orally or via gastrostomy/jejunostomy tube (G/J-tube). Fifteen patients were determined to be eligible for efficacy assessments.Dose adjustment was permitted to a maximum of 1.0 mg/kg/day and a minimum of 0.25 mg/kg/day.Thirteen patients enrolled in the open-label extension Summary of EMBOLD resultsRelutrigine was generally safe and well tolerated by patients during the EMBOLD study. Seven patients increased the daily dose from 0.5 to 1 mg/kg/day during the double-blind period of the study. No patient required dose reduction. The most common adverse events (AEs) were infections, vomiting, pyrexia, somnolence and constipation in patients receiving relutrigine. No patients discontinued due to an AE. Patients on relutrigine observed a placebo-adjusted reduction of 46% in countable motor seizures (log-transformed). Change in Global Impression of Improvement, assessed by the caregiver and clinician at week 16 for patients on relutrigine, showed an improvement (caregiver, clinician) in disruptive behavior (29%, 23%), communication (43%, 31%), seizure severity and intensity (71%, 62%) and alertness (57%, 69%). Eight patients have completed at least one 28-day period in the long-term extension of EMBOLD with a median reduction in motor seizures of 75%. Five patients achieved a 28-day seizure free status while receiving relutrigine, compared to none on placebo. Praxis to host a call on Tuesday, September 3 at 8:00 am ET to discuss the study results and next steps. To register for the call, please click here LINK The live webcast and replay will be available through the Events & Presentations page of the Investors and Media section of the company’s website at www.praxismedicines.com. About Relutrigine (PRAX-562) Relutrigine is a first-in-class small molecule in development for the treatment of developmental and epileptic encephalopathy (DEE) as a preferential inhibitor of persistent sodium current, shown to be a key driver of seizure symptoms in SCN2A-DEE and SCN8A-DEE. Relutrigine’s mechanism of sodium channel modulation is consistent with superior selectivity for disease state sodium channel (NaV) channel hyperexcitability. In vivo studies of relutrigine have demonstrated dose-dependent inhibition of seizures up to complete control of seizure activity in SCN2A, SCN8A and other DEE mouse models. Relutrigine has been generally well-tolerated in three Phase 1 studies and has demonstrated biomarker changes indicative of NaV channel blocking effects. Relutrigine has received Orphan Drug Designation (ODD) and Rare Pediatric Designation (RPD) from the FDA, and ODD from the European Medicines Agency for the treatment of SCN2A-DEE and SCN8A-DEE. To learn more about the EMBOLD study, please visit https://www.emboldstudy.org/. About Praxis  Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.    Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis’ future expectations, plans and prospects, or the clinical development of relutrigine, including with respect to the EMBOLD and related long-term extension study, the potential benefits of relutrigine to treat patients with aged 2-18 years with a diagnosis of early onset SCN2A-DEE or SCN8A-DEE and the potential impact to patients’ quality of life, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical trials; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials; and other risks concerning Praxis’ programs and operations as described in its Annual Report on Form 10-K for the year ended December 31, 2023 and other filings made with the Securities and Exchange Commission. Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Oral presentation by Dr. Jacqueline French to outline sustained monthly reduction in focal onset seizures during open-label extension of X-TOLE study Poster to present the trial design for Phase 3 X-ACKT clinical study evaluating XEN1101 in additional epilepsy indication of primary generalized tonic-clonic seizures VANCOUVER, British Columbia and BOSTON, April 24, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its upcoming oral and poster presentations at the 2023 American Academy of Neurology (AAN) Annual Meeting in Boston, MA. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are excited to showcase our XEN1101 epilepsy program at the 2023 AAN meeting. In particular, we are looking forward to the oral presentation by Dr. Jacqueline French, who will outline the promising results we are seeing in the ongoing open-label extension study of our Phase 2b X-TOLE clinical trial in focal onset seizures. XEN1101 represents the most advanced potassium channel modulator in clinical development for multiple indications, and our robust Phase 3 plans for XEN1101 include clinical trials already underway in focal onset seizures as well as primary generalized tonic-clonic seizures.” Jacqueline A. French, MD, Professor in the Department of Neurology at NYU Langone Health and Co-director of Epilepsy Clinical Trials at NYU Langone's Comprehensive Epilepsy Center; Founder/Director of the Epilepsy Study Consortium; and Chair of the XEN1101 X-TOLE Steering Committee, stated, “The interim analysis from an ongoing open-label extension study with XEN1101 builds upon the strong efficacy data generated in the Phase 2b X-TOLE clinical trial. Importantly, patients with epilepsy are experiencing continued seizure reduction and extended periods of seizure freedom. These data are encouraging for prescribing physicians who continue to seek new, differentiated therapeutics that improve upon existing options. I believe, as XEN1101 progresses through Phase 3 studies, these results also provide further hope for the many patients who experience the debilitating impacts of focal seizures, even while taking multiple anti-seizure medications.” 2023 AAN Presentation Details: Title: “XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b Study (X-TOLE) in Adults With Focal Epilepsy” Format: Oral Presentation #008, Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Outcomes Presenter: Jacqueline French, New York University Grossman School of Medicine and NYU Langone Health, New York, NY, USA Date/Time: Thursday, April 27, 2023 at 2:24 pm-2:36 pm ET Highlights: During the open-label extension (OLE), there was a sustained monthly reduction in seizure frequency (80%–90% seizure reduction as measured by median percent change) from the double-blind period baseline. Seizure freedom for ≥6-month and ≥12-month consecutive durations was achieved in 17.5% and 10.5% of patients, respectively. XEN1101 continues to be generally well-tolerated in the OLE with adverse events consistent with prior results and other anti-seizure medications. Title: “A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures” Format: Poster Session 11, #012 Lead Author: Antonio Gil-Nagel, Hospital Ruber Internacional, Madrid, Spain Date/Time: Wednesday, April 26, 2023 at 11:45 am-12:45 pm Highlights: Xenon has initiated a Phase 3 clinical trial, called X-ACKT, to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS). This multicenter, randomized, double-blind, placebo-controlled study will evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in approximately 160 patients with PGTCS. The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the double-blind period of XEN1101 compared to placebo. Other AAN Activities: On Sunday, April 23, 2023, Dr. Christopher Kenney, Xenon’s Chief Medical Officer, hosted a presentation entitled “XEN1101, a Novel Potassium Channel Opener in Clinical Trials for Epilepsy” on the Emerging Neurologic Care Presentation Stage in the Exhibit Hall. In addition to the posters noted above, Xenon is hosting a booth (#1575) in the Exhibit Hall, which is scheduled to be open from 11:30 am ET on Sunday, April 23, 2023 until 4 pm ET on Wednesday, April 26, 2023. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit . Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of our and our partners’ product candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in our XEN1101 and other development programs; and our ability to obtain regulatory approval of XEN1101 and our other product candidates. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; any of our or our collaborators’ product candidates, including XEN1101, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of the ongoing COVID-19 pandemic on our research and clinical development plans and timelines and results of operations, including impact on our clinical trial sites, collaborators, regulatory agencies and related review times, and contractors who act for or on our behalf, may be more severe and more prolonged than currently anticipated; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Investor/Media Contact: Jodi Regts Xenon Pharmaceuticals Inc. Phone: 604.484.3353 Email: investors@xenon-pharma.com